US Diabetes Care Drugs Market Size
Study Period | 2018- 2028 |
Base Year For Estimation | 2022 |
Forecast Data Period | 2023 - 2028 |
Market Size (2023) | USD 31.43 Billion |
Market Size (2028) | USD 37.69 Billion |
CAGR (2023 - 2028) | 3.70 % |
Major Players*Disclaimer: Major Players sorted in no particular order |
Need a report that reflects how COVID-19 has impacted this market and its growth?
US Diabetes Care Drugs Market Analysis
The United States Diabetes Care Drugs Market size is expected to grow from USD 31.43 billion in 2023 to USD 37.69 billion by 2028, at a CAGR of 3.70% during the forecast period (2023-2028).
COVID-19 has carved an especially fatal route through the 1 in 10 diabetics in the United States, including those who never contracted the virus. Because, when the epidemic struck, those with the chronic condition were already in worse form than they had been in years. It took the fatal COVID-19 outbreak to highlight a larger, more intractable public-health catastrophe in the United States: for more than a decade, the world's richest country has been losing the war against diabetes. COVID-19, which has killed over 600,000 individuals in the United States, has had a particularly devastating impact on millions of diabetic Americans. Early on, doctors and scientists recognized that many critically ill coronavirus patients also had a chronic condition. According to the Centers for Disease Control and Prevention (CDC), 40% or more of those who died from COVID-19 also had diabetes.
Based on drugs, the insulin segment holds a significant share in the market. Over 100 million people around the world need insulin, including all the people suffering from Type-1 diabetes and between 10% and 25% of people with Type-2 diabetes. Production of insulin is very complex, and there are very few companies in the market that manufacture insulin. Due to this, there is high competition between these manufacturers, who always strive to meet the patient's needs to supply the best-quality insulin.
US Diabetes Care Drugs Market Trends
Oral-Anti Diabetes Drugs Segment is Having the Highest Market Share in Current Year
The Oral-Anti Diabetes Drugs segment is expected to increase with a CAGR of over 5.4 % during the forecast period, mainly due to the demand from the diabetes population, which was more than 26 million by the end of the forecast period.
According to the International Diabetes Federation, diabetes patients will spend USD 966 billion in 2021, with Type 1 diabetes patients spending most of their money on insulin medicines. Only a small percentage of Type 2 diabetes patients require insulin. Although Type 1 diabetes affects just 10% of the population, their insulin consumption is greater. Increased knowledge of the advantages of insulin for diabetes patients, particularly in emerging nations, is driving the demand for insulin. Other reasons, such as quick advancement in insulin delivery methods, medication and analog research by major pharmaceutical firms, and an increase in the elderly and obese population, may fuel the insulin market's growth.
In the Oral Anti Diabetes Drugs segment, Metformin has the highest share. Metformin is a biguanide medication used to treat type 2 diabetes. It is given for "off-label" usage in patients suffering from diseases such as insulin resistance. Since introducing Metformin into T2DM therapy, many patients have been effectively treated with this internationally available medicine with a favorable risk/benefit profile recommended as a first-line prescription by IDF guidelines. As a result, Metformin remains the most prescribed oral antidiabetic drug globally, accounting for 45-50% of all prescriptions and being used by over 150 million individuals each year. Long-term favorable experience with metformin usage, solid evidence of clinical efficacy and safety, high adherence rate, cheap cost, broad availability, and cost-effectiveness all contribute to the large market share.
Thus, the above factors are expected to drive the market growth over the forecast period.
Increasing Diabetes Population in the United States
The United States dominates the global insulin therapeutics market, owing to the high prevalence of diabetes in the region because of the sedentary lifestyle and the launch of new drugs. The United States is expected to grow tremendously during the forecast period, owing to factors such as the high prevalence of obesity and increasing awareness regarding diabetes care. North America remained the largest market for insulin drugs, primarily due to high demand from the United States. Diabetic drugs are medicines developed to stabilize and control blood glucose levels among people with diabetes. Diabetic drugs are commonly used to manage diabetes. Diabetic drugs have been potential candidates for treating diabetic patients affected by SARS-CoV-2 infection during the COVID-19 pandemic. In North America, till April 2022, the United States had the highest number of COVID cases, around 82 million, and the country also registered the highest death rate. The pandemic has increased remote care from patients and providers and removed many long-standing regulatory barriers. In July 2022, Zydus Lifesciences announced that it had received final approval from the USFDA to market Empagliflozin and Metformin Hydrochloride tablets in multiple strengths. Empagliflozin and Metformin Hydrochloride tablets are used with proper diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. They are also used to lower the risk of cardiovascular death in patients with type 2 diabetes mellitus and established cardiovascular disease.
In January 2020, Novo Nordisk announced that the US Food and Drug Administration (FDA) had approved Fiasp (insulin aspart injection) 100 u/mL as a new mealtime insulin option for children with diabetes. Such developments are expected to increase the sales of Fiasp during the forecast period.
Thus, the above factors are expected to drive the market growth over the forecast period.
US Diabetes Care Drugs Industry Overview
Manufacturers have constantly innovated to compete and battle in the industry under study. According to a new study on the SGLT2 Class (Jardiance, Farxiga), medicine aids in treating renal and cardiovascular illnesses.
US Diabetes Care Drugs Market Leaders
Eli Lilly
Boehringer Ingelheim
Astrazeneca
Sanofi
NovoNordisk
*Disclaimer: Major Players sorted in no particular order
US Diabetes Care Drugs Market News
- November 2022: the U.S. Food and Drug Administration approved Tzield (teplizumab-mzwv) injection to delay the onset of stage 3 type 1 diabetes in adults and pediatric patients 8 years and older who currently have stage 2 type 1 diabetes.
- May 2022: the U.S. Food and Drug Administration approved Mounjaro (tirzepatide) injection to improve blood sugar control in adults with type 2 diabetes as an addition to diet and exercise. Mounjaro was effective at improving blood sugar and was more effective than the other diabetes therapies with which it was compared in clinical studies.
US Diabetes Care Drugs Market Report - Table of Contents
1. INTRODUCTION
1.1 Study Assumptions and Market Definition
1.2 Scope of the Study
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.3 Market Restraints
4.4 Porter's Five Forces Analysis
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Consumers
4.4.3 Threat of New Entrants
4.4.4 Threat of Substitute Products and Services
4.4.5 Intensity of Competitive Rivalry
5. MARKET SEGMENTATION
5.1 Oral Anti-diabetic drugs
5.1.1 Biguanides
5.1.1.1 Metformin
5.1.2 Alpha-Glucosidase Inhibitors
5.1.2.1 Alpha-Glucosidase Inhibitors
5.1.3 Dopamine D2 receptor agonist
5.1.3.1 Bromocriptin
5.1.4 SGLT-2 inhibitors
5.1.4.1 Invokana (Canagliflozin)
5.1.4.2 Jardiance (Empagliflozin)
5.1.4.3 Farxiga/Forxiga (Dapagliflozin)
5.1.4.4 Suglat (Ipragliflozin)
5.1.5 DPP-4 inhibitors
5.1.5.1 Onglyza (Saxagliptin)
5.1.5.2 Tradjenta (Linagliptin)
5.1.5.3 Vipidia/Nesina(Alogliptin)
5.1.5.4 Galvus (Vildagliptin)
5.1.6 Sulfonylureas
5.1.6.1 Sulfonylureas
5.1.7 Meglitinides
5.1.7.1 Meglitinides
5.2 Insulins
5.2.1 Basal or Long Acting Insulins
5.2.1.1 Lantus (Insulin Glargine)
5.2.1.2 Levemir (Insulin Detemir)
5.2.1.3 Toujeo (Insulin Glargine)
5.2.1.4 Tresiba (Insulin Degludec)
5.2.1.5 Basaglar (Insulin Glargine)
5.2.2 Bolus or Fast Acting Insulins
5.2.2.1 NovoRapid/Novolog (Insulin Aspart)
5.2.2.2 Humalog (Insulin Lispro)
5.2.2.3 Apidra (Insulin Glulisine)
5.2.3 Traditional Human Insulins
5.2.3.1 Novolin/Actrapid/Insulatard
5.2.3.2 Humulin
5.2.3.3 Insuman
5.2.4 Biosimilar Insulins
5.2.4.1 Insulin Glargine Biosimilars
5.2.4.2 Human Insulin Biosimilars
5.3 Combination drugs
5.3.1 Insulin combinations
5.3.1.1 NovoMix (Biphasic Insulin Aspart)
5.3.1.2 Ryzodeg (Insulin Degludec and Insulin Aspart)
5.3.1.3 Xultophy (Insulin Degludec and Liraglutide)
5.3.2 Oral Combinations
5.3.2.1 Janumet (Sitagliptin and Metformin)
5.4 Non-Insulin Injectable drugs
5.4.1 GLP-1 receptor agonists
5.4.1.1 Victoza (Liraglutide)
5.4.1.2 Byetta (Exenatide)
5.4.1.3 Bydureon (Exenatide)
5.4.1.4 Trulicity (Dulaglutide)
5.4.1.5 Lyxumia (Lixisenatide)
5.4.2 Amylin Analogue
5.4.2.1 Symlin (Pramlintide)
6. MARKET INDICATORS
6.1 Type-1 Diabetic Population
6.2 Type-2 Diabetic Population
7. COMPETITIVE LANDSCAPE
7.1 COMPANY PROFILES
7.1.1 Takeda
7.1.2 Novo Nordisk
7.1.3 Pfizer
7.1.4 Eli Lilly
7.1.5 Janssen Pharmaceuticals
7.1.6 Astellas
7.1.7 Boehringer Ingelheim
7.1.8 Merck And Co.
7.1.9 AstraZeneca
7.1.10 Bristol Myers Squibb
7.1.11 Novartis
7.1.12 Sanofi
- *List Not Exhaustive
8. MARKET OPPORTUNITIES AND FUTURE TRENDS
US Diabetes Care Drugs Industry Segmentation
Diabetes or diabetes mellitus describes a group of metabolic disorders characterized by a high blood sugar level in a person. With diabetes, the body either does not produce enough insulin or the body's cells do not respond properly to insulin, or both. The United States Diabetes Care Drugs Market witnessed USD 29 billion in the current year and is anticipated to register a CAGR of over 3% during the forecast period. The United States Diabetes Care Drugs Market is segmented into Drugs (Oral Anti-diabetic Drugs, Insulin, Non-insulin Injectable Drugs, and Combination Drugs). The report offers the value (in USD million) and volume (in Units million) for the above segments.
Oral Anti-diabetic drugs | ||||||
| ||||||
| ||||||
| ||||||
| ||||||
| ||||||
| ||||||
|
Insulins | |||||||
| |||||||
| |||||||
| |||||||
|
Combination drugs | |||||
| |||||
|
Non-Insulin Injectable drugs | |||||||
| |||||||
|
US Diabetes Care Drugs Market Research FAQs
How big is the US Diabetes Care Drugs Market?
The US Diabetes Care Drugs Market size is expected to reach USD 31.43 billion in 2023 and grow at a CAGR of 3.70% to reach USD 37.69 billion by 2028.
What is the current US Diabetes Care Drugs Market size?
In 2023, the US Diabetes Care Drugs Market size is expected to reach USD 31.43 billion.
Who are the key players in US Diabetes Care Drugs Market?
Eli Lilly, Boehringer Ingelheim, Astrazeneca, Sanofi and NovoNordisk are the major companies operating in the US Diabetes Care Drugs Market.
United States Diabetes Care Drugs Industry Report
Statistics for the 2023 US Diabetes Care Drugs market share, size and revenue growth rate, created by Mordor Intelligence™ Industry Reports. US Diabetes Care Drugs analysis includes a market forecast outlook to for 2023 to 2028 and historical overview. Get a sample of this industry analysis as a free report PDF download.